Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Surgical Critical Care for the Trauma Patient with Cardiac Disease.

Woll MM, Maerz LL.

Anesthesiol Clin. 2016 Dec;34(4):669-680. doi: 10.1016/j.anclin.2016.06.004. Review.

PMID:
27816127
2.

Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients.

Gates JD, Carmichael MG, Benavides LC, Holmes JP, Hueman MT, Woll MM, Ioannides CG, Robson CH, McLeod DG, Ponniah S, Peoples GE.

J Am Coll Surg. 2009 Feb;208(2):193-201. doi: 10.1016/j.jamcollsurg.2008.10.018.

PMID:
19228530
3.

Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

Peoples GE, Holmes JP, Hueman MT, Mittendorf EA, Amin A, Khoo S, Dehqanzada ZA, Gurney JM, Woll MM, Ryan GB, Storrer CE, Craig D, Ioannides CG, Ponniah S.

Clin Cancer Res. 2008 Feb 1;14(3):797-803. doi: 10.1158/1078-0432.CCR-07-1448.

4.

Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients.

Hueman MT, Dehqanzada ZA, Novak TE, Gurney JM, Woll MM, Ryan GB, Storrer CE, Fisher C, McLeod DG, Ioannides CG, Ponniah S, Peoples GE.

Clin Cancer Res. 2005 Oct 15;11(20):7470-9.

5.

Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.

Peoples GE, Gurney JM, Hueman MT, Woll MM, Ryan GB, Storrer CE, Fisher C, Shriver CD, Ioannides CG, Ponniah S.

J Clin Oncol. 2005 Oct 20;23(30):7536-45. Epub 2005 Sep 12.

PMID:
16157940
6.

Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer.

Woll MM, Hueman MT, Ryan GB, Ioannides CG, Henderson CG, Sesterhan IA, Shrivasta S, McLeod DG, Moul JW, Peoples GE.

Int J Oncol. 2004 Dec;25(6):1769-80.

PMID:
15547716
7.

Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients.

Woll MM, Fisher CM, Ryan GB, Gurney JM, Storrer CE, Ioannides CG, Shriver CD, Moul JW, McLeod DG, Ponniah S, Peoples GE.

J Clin Immunol. 2004 Jul;24(4):449-61.

PMID:
15163902
8.

Bilateral spontaneous dissection of the internal carotid arteries--a case report.

Woll MM, Goff JM Jr, Gillespie DL, Minken SL.

Vasc Surg. 2001 May-Jun;35(3):221-4.

PMID:
11452349

Supplemental Content

Support Center